reports
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Sharad Kumar S.P
- Wim Lewi
Inventiva annonce la recommandation positive du quatrième DMC de l’étu...
Inventiva annonce la recommandation positive du quatrième DMC de l’étude clinique NATiV3 Phase III avec lanifibranor dans la MASH/NASH Le Data Monitoring Committee recommande sur la base d’une revue planifiée des données de sécurité que l’étude clinique de Phase III continue sans modification du protocole actuel.L’évaluation réalisée par le DMC est basée sur l’examen non masqué des données de sécurité provenant de plus de 900 patients randomisés dans les cohortes principale et exploratoire, incluant respectivement plus de 360 et plus de 80 patients ayant été traités pendant plus de 48 et 72...
Inventiva announces the positive recommendation of the fourth DMC of t...
Inventiva announces the positive recommendation of the fourth DMC of the NATiV3 Phase III clinical trial with lanifibranor in patients with MASH/NASH The Data Monitoring Committee recommended to continue the clinical trial without modification of the current protocol, based on the pre-planned review of safety data.The recommendation was based on the unblinded review by the DMC of safety data from more than 900 patients randomized in the main and exploratory cohorts, including more than 360 and 80 patients that have been treated for more than 48 and 72 weeks, respectively.The patient who exp...
ERAMET - Informations relatives au nombre total de droits de vote et d...
ERAMET - Informations relatives au nombre total de droits de vote et d’actions au 30 avril 2024 Dénomination sociale de l'émetteur : ERAMET SA10 boulevard de Grenelle75015 Paris632 045 381 RCS PARIS Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 223-8 II du code de commerce et l’article 223-16 du règlement général de l’Autorité des marchés financiers N° LEI : 549300LUH78PG2MP6N64 Date d'arrêté des informationsNombre total d'actions composant le capitalNombre total de droits de vote 30 avril 2024 28 755 047Nombre de droits de vote théoriqu...
- Carole Braudeau
- Guy Sips
- Jacob Mekhael
- Sharad Kumar S.P
- Wim Hoste
- Jacob Mekhael
Inventiva Additional NATIVE data supportive of lanifibranor's benefit ...
Yesterday, Inventiva announced the publication of additional results from the phase 2 (NATIVE) trial of lanifibranor in MASH (previously NASH), which are in line with previously reported benefits on cardiometabolic outcomes, leading the stock to trade +7% intraday. We believe the results continue to support lanifibranor's positioning in MASH, and look forward to the last patient first visit (expected by 1H24) in the phase 3 (NATiV3) trial. We reiterate our BUY rating and € 10 TP.
Moody's Ratings affirms Eramet's Ba2 ratings; outlook stable
Moody's Ratings (Moody's) has today affirmed the Ba2 long-term corporate family rating (CFR) and Ba2-PD probability of default rating (PDR) of French mining and metallurgical company ERAMET S.A. ("Eramet" or "the group"). Concurrently, Moody's affirmed the Ba2 instrument ratings on the group's €300 ...
LACROIX : First-quarter 2024 revenue of €186.3 million (-4.4%), marked...
LACROIX : First-quarter 2024 revenue of €186.3 million (-4.4%), marked by a high comparative base for Electronics and continued strong momentum for City and Environment divisions. 13/05/2024 First-quarter 2024 revenue of €186.3 million (-4.4%), marked by a high comparative base for Electronics and continued strong momentum for City and Environment divisions Sales and profitability targets for 2024 confirmed Revenue in millions of eurosQ1 2024Q1 2023Change Electronics activity 138,4152,5-9,2%City activity26,023,3+11,5%Environment activity21,818,9+15,4%Total 186,3194,8-4,4%Excl. Road Sig...
LACROIX : Un chiffre d’affaires de 186,3 M€ au premier trimestre 2024 ...
LACROIX : Un chiffre d’affaires de 186,3 M€ au premier trimestre 2024 (-4,4%), marqué par une base de comparaison élevée pour Electronics et une dynamique toujours forte sur City et Environment. 13/05/2024 Un chiffre d’affaires de 186,3 M€ au premier trimestre 2024 (-4,4%), marqué par une base de comparaison élevée pour Electronics et une dynamique toujours forte sur City et Environment Confirmation des objectifs d’activité et de rentabilité pour 2024 CA en millions d’eurosT1 2024T1 2023VariationActivité Electronics138,4152,5-9,2%Activité City26,023,3+11,5%Activité Environment ...
- Anthony Dick
- Michael Foundoukidis
- Anthony Dick
- Michael Foundoukidis
- Emna Ben Bdira
- Maxime Kogge
Eramet : Les planètes enfin alignées, objectif de cours réhaussé à 157...
>L'envolée des cours du manganèse devrait se poursuivre - Après une année 2023 difficile, les planètes sont enfin alignées pour Eramet avec la conjonction de prix et de changes bien orientés, d’une production en hausse et de coûts bien maîtrisés. L’événement dominant est évidemment l’envolée des cours du manganèse depuis l’arrêt en mars de la production de GEMCO, la filiale australienne de South32. Le rallye s’est accéléré avec l’annonce par South32 en avril qu’il ne ...
- Emna Ben Bdira
- Maxime Kogge
Eramet : The planets have finally aligned; target price lifted to € 15...
>The surge in manganese prices is well underway - Following a tough year in 2023, the planets have finally aligned for Eramet, with the combination of prices and costs on a positive trend, improved production and well controlled costs. The recent highlight is the surge in manganese prices following the March production shutdown of GEMCO, South32’s Australian entity. The rally accelerated with South32’s announcement in April that it would not be able to return to a nor...
Inventiva announces the publication in Nature Communications of additi...
Inventiva announces the publication in Nature Communications of additional results from NATIVE Phase IIb clinical trial demonstrating improvement of markers of cardiometabolic health in patients with MASH/NASH treated with lanifibranor Improvements were observed for insulin resistance (insulin levels, HOMA-IR), lipid metabolism (triglycerides, HDL-cholesterol, apolipoproteins), control of glycemia (HbA1c, fasting glucose (FG) levels), systemic inflammation (hs-CRP, ferritin), hepatic steatosis and diastolic blood pressure.Among the patients who had prediabetes at study entry and were treate...
Inventiva annonce la publication dans Nature Communications de résulta...
Inventiva annonce la publication dans Nature Communications de résultats complémentaires de l’étude clinique de Phase II NATIVE démontrant l’amélioration de marqueurs de santé cardiométabolique chez les patients atteints de MASH/NASH traité Des améliorations ont été observées au niveau de la résistance à l'insuline (taux d'insuline, HOMA-IR), du métabolisme lipidique (triglycérides, HDL-cholestérol, apolipoprotéines), du contrôle de la glycémie (HbA1c, taux de glucose à jeun), de l'inflammation systémique (hs-CRP, ferritine), de la stéatose hépatique et de la pression artérielle diastolique...
Availability of the documents of the Ordinary and Extraordinary Shareh...
Availability of the documents of the Ordinary and Extraordinary Shareholders’ General Meeting to be held on May 30th, 2024 Paris, May 7, 2024, 5:45 pm PRESS RELEASE Availability of the documents of the Ordinary and Extraordinary Shareholders’ General Meeting to be held on May 30th, 2024 Eramet’s shareholders are invited to participate in the Ordinary and Extraordinary Shareholder’s General Meeting, which will take place on: Thursday, May 30th, 2024, at 10:00 a.m. (Paris time), at Eramet’s head office, 10 boulevard de Grenelle 75015 Paris. Detailed participation procedures are outlined...
GTT: Monthly disclosure of the total number of voting rights and share...
GTT: Monthly disclosure of the total number of voting rights and shares composing the share capital Monthly disclosure of the total number of voting rights and shares composing the share capital Articles L. 233-8-II of the French Commercial Code and 223-16 of the General Regulation of the Autorité des Marchés Financiers Saint-Rémy-lès-Chevreuse, May 3, 2024 DateTotal number of sharesTheoretical total number of voting rights1Net total number of voting rights2April 30, 202437,078,35737,078,35736,952,072 Investor Relations Contact / 87 1 Calculated on t...
LACROIX announces the final sale of the Road Signs segment.
LACROIX announces the final sale of the Road Signs segment. LACROIX announces the final saleof the Road Signs segment LACROIX announces that it has finalized the sale of its Road Signs segment to the industrial investment company AIAC (American Industrial Acquisition Corporation). The two companies had entered into exclusive negotiations on December 14, 2023. The sale, which has been approved by the relevant authorities, will take effect on April 30, 2024, at which time the segment will be removed from the Group's scope of consolidation. This divestment reflects LACROIX's intention to f...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.